<DOC>
	<DOCNO>NCT02227355</DOCNO>
	<brief_summary>This study aim evaluate effectiveness Rotigotine Levodopa combination therapy young old patient Parkinson 's Disease real life condition . Effects ability perform activity daily live , sleep , medication dose factor assess .</brief_summary>
	<brief_title>Evaluating Effectiveness Neupro® ( Rotigotine ) L-dopa Combination Therapy Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>The following selection criterion must follow patient enter Noninterventional Study ( NIS ) : The decision treat physician prescribe Rotigotine transdermal patch make participate NIS due clinical therapeutic indication ( e.g. , intolerance and/or ineffectiveness another dopamine agonist ) The patient either male female 18 year age A Patient Data Consent form sign dated patient legal representative The patient idiopathic Parkinson 's Disease , receive Rotigotine within 28 day prior Baseline Visit willing participate questionnaire base assessments The patient receive Ldopa monotherapy combination therapy compose Ldopa dopamine agonist Rotigotine The patient Ldopa therapy least 6 month respond initial Ldopa therapy The patient Hoehn Yahr stage score 1 4 . Patients exclude study participate clinical study medication medical device within 3 month prior Baseline participate clinical study time inclusion already participate current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Rotigotine</keyword>
	<keyword>Transdermal patch</keyword>
	<keyword>NEUPART</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Noninterventional</keyword>
	<keyword>Combination therapy</keyword>
</DOC>